NOTE: You are only paying for the exam and prescription, not the medication. We will send your prescription to Eli Lilly Direct Pharmacy to hand the fulfilment and you will need to pay them directly. We have no control over their inventory, back order, shipping time, etc.

Zepbound® for Weight Loss – The New Standard in Obesity Treatment

Zepbound® (tirzepatide) is a groundbreaking FDA-approved, once-weekly injectable medication for chronic weight management in adults. Developed by Eli Lilly and approved in late 2023, Zepbound is the first and only medication that combines dual-incretin hormone action—offering superior results compared to earlier GLP-1 therapies like Wegovy®.

Zepbound is approved for adults with:

• A BMI of 30 or greater (obesity)

• Or a BMI of 27 or greater (overweight) with at least one weight-related medical condition such as type 2 diabetes, high blood pressure, or high cholesterol

How Zepbound® Works

Zepbound contains tirzepatide, a dual agonist of:

• GLP-1 (glucagon-like peptide-1)

• GIP (glucose-dependent insulinotropic polypeptide)

This “twin incretin” mechanism enhances the body’s ability to:

• Regulate blood sugar

• Control appetite

• Delay gastric emptying

• Boost fat metabolism

• Improve insulin sensitivity

The result is faster, more powerful weight loss with additional metabolic benefits compared to GLP-1-only medications like semaglutide.

Efficacy and Results

Zepbound has shown unmatched weight loss results in clinical trials, with participants losing up to 22.5% of their starting body weight over 72 weeks.

Key outcomes from the SURMOUNT-1 study:

• 15 mg tirzepatide: Average of 52 lbs lost (~22.5% of body weight)

• Compared to placebo: ~5 lbs lost (~2.4%)

• More than 80% of users lost ≥15% of their body weight

This makes Zepbound the most effective FDA-approved weight loss medication currently available.